These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 33850601)
1. Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital. Paoletti G; Racca F; Piona A; Melone G; Merigo M; Puggioni F; Ferri S; Azzolini E; Lagioia M; Lamacchia D; Cataldo G; Cecconi M; Canonica GW; Heffler E World Allergy Organ J; 2021 May; 14(5):100541. PubMed ID: 33850601 [TBL] [Abstract][Full Text] [Related]
2. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Sellaturay P; Gurugama P; Harper V; Dymond T; Ewan P; Nasser S Clin Exp Allergy; 2022 Jan; 52(1):12-17. PubMed ID: 34822190 [TBL] [Abstract][Full Text] [Related]
3. Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines. Nappi E; Racca F; Piona A; Messina MR; Ferri S; Lamacchia D; Cataldo G; Costanzo G; Del Moro L; Puggioni F; Canonica GW; Heffler E; Paoletti G Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37243019 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of pediatric patients with suspected polyethylene glycol and polysorbate allergy before mRNA SARS-CoV2 vaccination. Karaaslan BG; Burtecene N; Mustu U; Ocak S; Kasapcopur O; Kıykım A; Cokugras H Allergol Immunopathol (Madr); 2023; 51(3):174-180. PubMed ID: 37169575 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 and allergy - what have we learned after two and a half years? Brockow K; Wang R; Mathes S; Bent R; Faihs V; Eberlein B; Darsow U; Biedermann T Allergol Select; 2023; 7():101-112. PubMed ID: 37056446 [TBL] [Abstract][Full Text] [Related]
7. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Greenhawt M; Abrams EM; Shaker M; Chu DK; Khan D; Akin C; Alqurashi W; Arkwright P; Baldwin JL; Ben-Shoshan M; Bernstein J; Bingemann T; Blumchen K; Byrne A; Bognanni A; Campbell D; Campbell R; Chagla Z; Chan ES; Chan J; Comberiati P; Dribin TE; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Grayson MH; Horner CC; Hourihane J; Katelaris CH; Kim H; Kelso JM; Lang D; Ledford D; Levin M; Lieberman J; Loh R; Mack D; Mazer B; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Oppenheimer J; Perrett KP; Ramsey A; Rank M; Robertson K; Sheikh J; Spergel JM; Stukus D; Tang MLK; Tracy JM; Turner PJ; Whalen-Browne A; Wallace D; Wang J; Waserman S; Witry JK; Worm M; Vander Leek TK; Golden DBK J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3546-3567. PubMed ID: 34153517 [TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis is a rare reaction in COVID-19 vaccination. Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336 [TBL] [Abstract][Full Text] [Related]
9. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis. Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528 [TBL] [Abstract][Full Text] [Related]
10. Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: The McGill University Health Centre experience. ALMuhizi F; Fein M; Gabrielli S; Gilbert L; Tsoukas C; Ben-Shoshan M; Copaescu AM; Isabwe GAC Ann Allergy Asthma Immunol; 2022 Aug; 129(2):182-188.e1. PubMed ID: 35609744 [TBL] [Abstract][Full Text] [Related]
11. [Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia]. Leonidou Floruß E; Demidova A; Hofmann SC; Balakirski G Dermatologie (Heidelb); 2023 Jul; 74(7):511-519. PubMed ID: 37140637 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
13. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. Wolfson AR; Robinson LB; Li L; McMahon AE; Cogan AS; Fu X; Wickner P; Samarakoon U; Saff RR; Blumenthal KG; Banerji A J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3308-3320.e3. PubMed ID: 34166844 [TBL] [Abstract][Full Text] [Related]
14. Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose. AlMuhizi F; Ton-Leclerc S; Fein M; Tsoukas C; Garvey LH; Lee D; Ben-Shoshan M; Isabwe GAC; Copaescu AM Front Allergy; 2022; 3():825164. PubMed ID: 35386647 [TBL] [Abstract][Full Text] [Related]
15. Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy). Filon FL; Lazzarato I; Patriarca E; Iavernig T; Peratoner A; Perri G; Ponis G; Rocco G; Cegolon L Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298481 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines: anaphylaxis and anxiety : A case study from an allergy unit. Teufelberger AR; Dan AR; Irmler L; Wolf P; Kränke B Wien Klin Wochenschr; 2024 Nov; 136(21-22):590-597. PubMed ID: 39259224 [TBL] [Abstract][Full Text] [Related]
17. COVID vaccination can be performed in patients with a history of allergic reactions to the vaccines or their components: experience from a specialist clinic in South Australia. Tunbridge M; Perkins G; Lee M; Salehi T; Ryoo D; Kette F; Smith W; Gold M; Le TA; Yuson C; Hissaria P Intern Med J; 2022 Nov; 52(11):1884-1890. PubMed ID: 35848521 [TBL] [Abstract][Full Text] [Related]